Clonal spread of fluoroquinolone non-susceptible Streptococcus pyogenes

被引:33
作者
Malhotra-Kumar, S
Lammens, C
Chapelle, S
Mallentjer, C
Weyler, J
Goossens, H
机构
[1] Univ Antwerp, Dept Epidemiol & Community Med, B-2610 Antwerp, Belgium
[2] Univ Antwerp, Belgian Reference Ctr Grp A Streptococcus, B-2610 Antwerp, Belgium
关键词
S; pyogenes; antibiotic resistance; molecular mechanisms;
D O I
10.1093/jac/dki011
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Fluoroquinolones are an important group of antibiotics widely used in adults, and, despite the absence of official approval, these drugs are also used in children. So far, resistance to fluoroquinolones in Streptococcus pyogenes is very rare. Methods: During a national surveillance programme in Belgium from 1999 to 2002, 2793 non-duplicate S. pyogenes recovered from tonsillopharyngitis patients were screened for fluoroquinolone resistance. Mutations in topoisomerase genes and the presence of any efflux pump activity were investigated to elucidate the fluoroquinolone resistance mechanisms. Clonality was assessed by pulsed-field gel electrophoresis (PFGE) and emm typing. Results: Non-susceptibility to fluoroquinolones, defined as ciprofloxacin MIC greater than or equal to 2 mg/L, was identified in 152 (5.4%) of 2793 S. pyogenes. Fifty-five (36%) fluoroquinolone non-susceptible isolates were investigated for known resistance mechanisms; all showed mutations in parC, and 29 (19%) isolates also in parE; antibiotic efflux was not noted. Two major PFGE types comprised 88% of fluoroquinolone non-susceptible S. pyogenes and belonged to serotypes emm6 and emm75. Overall, emm6 and emm75 constituted >90% of all fluoroquinolone non-susceptible isolates and showed a significant temporal and geographical shift within Belgian provinces. Although fluoroquinolone-susceptible S. pyogenes also showed fluctuations in the predominant S. pyogenes serotypes, emm6 or emm75 were under-represented in this population. Approx. 55% of the fluoroquinolone non-susceptible isolates were recovered from children ( less than or equal to16 years). Conclusions: We show here, for the first time, a multi-clonal spread of fluoroquinolone non-susceptible S. pyogenes exhibiting a known resistance mechanism. Non-susceptibility to fluoroquinolones in paediatric isolates is of concern.
引用
收藏
页码:320 / 325
页数:6
相关论文
共 28 条
[1]  
AHMED M, 1993, J BIOL CHEM, V268, P11086
[2]   parC mutation conferring ciprofloxacin resistance in Streptococcus pyogenes BM4513 [J].
Alonso, R ;
Galimand, M ;
Courvalin, P .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3686-3687
[3]  
[Anonymous], 2002, M100S12 NCCLS
[4]   DYNAMICS OF STREPTOCOCCAL INFECTIONS IN A DEFINED POPULATION OF CHILDREN - SEROTYPES ASSOCIATED WITH SKIN AND RESPIRATORY-INFECTIONS [J].
ANTHONY, BF ;
KAPLAN, EL ;
WANNAMAKER, LW ;
CHAPMAN, SS .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 1976, 104 (06) :652-666
[5]   Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae:: Contributions of type II topoisomerase mutations and efflux to levels of resistance [J].
Bast, DJ ;
Low, DE ;
Duncan, CL ;
Kilburn, L ;
Mandell, LA ;
Davidson, RJ ;
de Azavedo, JCS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (11) :3049-3054
[6]   The prevalence of group A streptococcal throat carriage in Al Ain, United Arab Emirates [J].
Dawson, KP ;
Ameen, AS ;
Nsanze, H ;
BinOthman, S ;
Mustafa, N .
ANNALS OF TROPICAL PAEDIATRICS, 1996, 16 (02) :123-127
[7]   Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates [J].
Descheemaeker, P ;
Chapelle, S ;
Lammens, C ;
Hauchecorne, M ;
Wijdooghe, M ;
Vandamme, P ;
Ieven, M ;
Goossens, H .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (02) :167-173
[8]   Antibacterial resistance among children with community-acquired respiratory tract infections (PROTEKT 1999-2000) [J].
Felmingham, D ;
Farrell, DJ ;
Reinert, RR ;
Morrissey, I .
JOURNAL OF INFECTION, 2004, 48 (01) :39-55
[9]   Fluoroquinolones in paediatrics: a risk for the patient or for the community? [J].
Gendrel, D ;
Chalumeau, M ;
Moulin, F ;
Raymond, J .
LANCET INFECTIOUS DISEASES, 2003, 3 (09) :537-546
[10]   Widespread use of fluoroquinolones versus emerging resistance in pneumococci [J].
Goldstein, EJC ;
Garabedian-Ruffalo, SM .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (12) :1505-1511